We provide molecular evidence in vivo that NSC61610 functions in a LANCL2-dependent manner during the recovery phase of infection, since the beneficial effects of NSC61610 treatment observed in wild-type mice are abrogated in LANCL2 knockout mice. This evidence concerns the gene LANCL2 and infection.